论文部分内容阅读
目的观察卡培他滨单药治疗老年晚期乳腺癌的临床疗效和毒性反应。方法 36例Ⅳ期老年乳腺癌患者均经病理组织学或细胞学检查确诊。治疗剂量卡培他滨:2500 mg/m2,分早晚2次餐后半小时口服,第1～14天,每3～4周重复,2周期后评价疗效。结果 36例患者均可评价,其中获完全缓解(CR)0例,部分缓解(PR)10例,稳定(SD)14例,进展(PD)12例,总有效率27.8%(10/36)。临床获益率(CR+PR+SD)66.7%(24/36),中位疾病进展时间(TTP)7.1个月。主要的毒副反应为手足综合症、腹泻、口腔炎,均可耐受,无化疗相关死亡。结论卡培他滨单药治疗老年晚期乳腺癌疗效确切,可明显改善患者生存质量,延长生存时间,副反应轻,耐受性良好并适合门诊治疗,是一种安全有效的姑息治疗方案。
Objective To observe the clinical efficacy and toxicity of capecitabine in the treatment of elderly patients with advanced breast cancer. Methods 36 patients with stage Ⅳ advanced breast cancer were diagnosed by histopathology or cytology. Therapeutic dose capecitabine: 2500 mg / m2, divided into two times a day morning and evening half an hour after oral administration, the first to 14 days, repeated every 3 to 4 weeks, 2 cycles after the evaluation of efficacy. Results All of the 36 patients were eligible for evaluation. Among them, 0 were complete remission (CR), 10 were partial remission (PR), 14 were stable (SD) and 12 were progressive. The total effective rate was 27.8% (10/36) . The clinical benefit rate (CR + PR + SD) was 66.7% (24/36) and the median progression time (TTP) was 7.1 months. The main side effects of hand-foot syndrome, diarrhea, stomatitis, can be tolerated, no chemotherapy-related deaths. Conclusion Capecitabine monotherapy for the treatment of elderly patients with advanced breast cancer is effective and can significantly improve the quality of life of patients, prolong the survival time, mild side effects, well tolerated and suitable for outpatient treatment is a safe and effective palliative treatment.